Zenas BioPharma, Inc.
ZBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001953926
No open-market purchases or sales by Zenas BioPharma, Inc. insiders were filed in the last 90 days; 144 institutions reported holding it in 13F filings for Q2 2026, worth $1.55B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +6 vs. previous quarter
- 144
- 13F valueReported value at the end of Q2 2026
- $1.55B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ZBIO, Q2 2026
No superinvestor reported holding ZBIO at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Zenas BioPharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 18, 2026 (view filing) | May 18 | Same day | Moulder Leon O JrChief Executive Officer | PPurchase | +60.0K | $16.88 | +$1.01M | +162.5%96.9K after | |
| Apr 29, 2026 (view filing) | Apr 28-29 | 1 day | Moulder Leon O JrChief Executive Officer | PPurchase | +60.0K | $17.79 | +$1.07M | +3.5%1.79M after | 2 lots |
| Apr 2, 2026 (view filing) | Mar 31 | 2 days | Lu HongboDirector | PPurchase | +3.77K | $18.63 | +$70.2K | +0.9%426.7K after | |
| Apr 1, 2026 (view filing)4:30 PM ET | Mar 31 | 1 day | Harwin Peter Evan and 3 othersDirector | PPurchase | +150.0K | $20.00 | +$3.00M | +6.8%2.36M after | |
| Mar 31, 2026 (view filing) | Mar 30-31 | 1 day | Moulder Leon O JrChief Executive Officer | PPurchase | +54.0K | $18.91 | +$1.02M | +3.2%1.73M after | 2 lots |
| Mar 31, 2026 (view filing) | Mar 31 | Same day | Lu HongboDirector | PPurchase | +75.0K | $20.00 | +$1.50M | +21.6%423.0K after | |
| Feb 13, 2026 (view filing) | Feb 11 | 2 days | Lu HongboDirector | PPurchase | +26.0K | $22.50 | +$584.7K | +8.1%348.0K after | |
| Feb 13, 2026 (view filing) | Feb 12-13 | 1 day | Allen Patricia LDirector | PPurchase | +19.9K | $25.16 | +$499.7K | New position19.9K after | 4 lots |
| Feb 3, 2026 (view filing) | Feb 2 | 1 day | Moulder Leon O JrChief Executive Officer | PPurchase | +57.0K | $17.96 | +$1.02M | +15.6%423.2K after | |
| Jan 9, 2026 (view filing) | Jan 7-9 | 2 days | Moulder Leon O JrChief Executive Officer | PPurchase | +100.0K | $16.39 | +$1.64M | +37.6%366.2K after | 3 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Zenas BioPharma, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 9,506,701 | $241.3M | 0.01% | +424,701+4.7% | Added |
| Sr One Capital Management, LP | 5,037,854 | $127.9M | 12.31% | 00.0% | Unchanged |
| NEA Management Company, LLC | 4,023,219 | $102.1M | 6.43% | 00.0% | Unchanged |
| Enavate Sciences GP, LLC | 3,919,159 | $99.5M | 28.80% | 00.0% | Unchanged |
| Federated Hermes, Inc. | 3,116,805 | $79.1M | 0.11% | −10,226−0.3% | Reduced |
| BlackRock, Inc. | 2,686,225 | $68.2M | 0.00% | +648,677+31.8% | Added |
| Capital International Investors | 2,502,912 | $63.5M | 0.01% | +68,912+2.8% | Added |
| Polar Capital Holdings Plc | 2,412,772 | $61.2M | 0.17% | −135,672−5.3% | Reduced |
| Royalty Pharma Sub-Manager, LLC | 2,388,150 | $60.6M | 25.05% | 00.0% | Unchanged |
| Fairmount Funds Management LLC | 2,359,025 | $59.9M | 3.96% | 00.0% | Unchanged |